This clinical trial studies how well measuring frailty and co-management works in improving outcomes in older patients with blood cancer. Frailty is a decline in health, including the loss of energy, physical ability, and mental ability, and can make it difficult for people to respond to treatment and more likely to have side effects. Identifying patients who are frail and scheduling visits with a geriatrician in the oncology clinic may improve outcomes in older patients with blood cancer.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02359838.
Locations matching your search criteria
United States
Massachusetts
Boston
Dana-Farber Cancer InstituteStatus: Active
Contact: Gregory Alan Abel
Phone: 617-632-2304
PRIMARY OBJECTIVES:
I. Characterize the prognostic value of frailty as compared to clinical prognostic models for older patients with blood cancers.
II. Determine if co-management of frail and pre-frail older adults with blood cancers by an embedded geriatrician improves outcomes.
OUTLINE: Patients categorized as pre-frail/frail are randomized to 1 of 2 groups. Patients categorized as robust are assigned to Group II.
GROUP I: Patients undergo a comprehensive geriatric assessment and receive routine oncology care with geriatric co-management.
GROUP II: Patients receive routine oncology care.
All patients undergo frailty assessment comprising of a grip strength test and short walking speed test for 10 minutes at baseline.
After completion of study, patients are followed up at 1 year.
Trial PhaseNo phase specified
Trial Typesupportive care
Lead OrganizationDana-Farber Harvard Cancer Center
Principal InvestigatorGregory Alan Abel
